Nov 22, 2018 · Specifically, we could distinguish GBM cell lines in the GD2 highly positive T98G (97 ± 1%), the GD2 middle-positive U87MG (57 ± 13%), and the GD2-negative A172 (2 ± 1%).

Oct 27, 2021 · Data highlighted a robust GD2 CAR antitumor potential in 2D and 3D glioblastoma models associated with a significant and CAR T-restricted increase of selected cytokines. Interestingly,...

Jun 1, 2023 · In the case of the U87 cell line, GD2-specific CAR-T in combination with Nivolumab demonstrated a cytotoxic efficiency of 40.47 ± 8.3% and residual elimination ability of 43.44 ± 7.83% at the fifth-round re-challenge, whereas treatment with CAR-T cells alone showed values of only 20.97 ± 3.38% and 24.08 ± 4.44%, respectively (Figs. 3 G and ...

U-87 MG is a cell line with epithelial morphology that was isolated from malignant gliomas from a male patient, likely with Glioblastoma. Use these cells in your neuroscience and immuno-oncology research.

Jul 7, 2023 · Flow cytometric assay showed that ~ 30% U87 LUCI cells were GD2 positive, indicating that not all U87 cells could be eliminated by GD2-specific CAR-mediated cytotoxicity but could be used as supplementary therapeutics for iNSCs TK /GCV system (Fig. 4B). A gene encoding GD2-specific CAR fused with EGFP was transduced into NK92 via lentivirus to ...

We aimed to developed a novel combined immunotherapeutic strategy to improve the treatment eficacy using genetically engineered PBMC-derived induced neural stem cells (iNSCs) expressing HSV-TK and second-generation CAR-NK cells against GBM.

Oct 31, 2020 · U87MG human glioma cell line and its drug resistant variant (U87DR), which were confirmed to be associated with low and high expression of cell surface GD2, were employed to compare the targeting efficacy.

U87 GBM cells with stemness features demonstrate increased cytotoxicity to NK cells in association with altered NKG2D ligand expression of NK cell activating receptor. Applying immune modulation to GBM treatment may be a promising adjuvant therapy in …

To assess the function of CAR-T cells in vitro, we co-cultured a range of GD2 + tumor cell lines with CAR-T cells in a real-time impedance-based cytotoxicity assay over 5 days.

Nov 22, 2018 · FACS analyses revealed that the three selected GBM cell lines differ for GD2 expression (Fig. 2a). Specifically, we could distinguish GBM cell lines in the GD2 highly positive T98G (97 ± 1%), the GD2 middle-positive U87MG (57 ± …